CLEC3B and hepatocellular carcinoma: In particular, for HCC, we found that the disease-specific survival (Figure 2A, HR = 0.26, 95% CI = 0.17 to 0.41, P = 4.6e−10), progression-free survival (Figure 2B, HR = 0.41, 95% CI = 0.3 to 0.56, P = 6.8e−09), overall survival (Figure 2C, HR = 0.34, 95% CI = 0.24 to 0.48, P = 4.4e−10), and relapse-free survival (Figure 2D, HR = 0.42, 95% CI = 0.3 to 0.59, P = 4.4e−07) were significantly reduced when the expression level of CLEC3B was low.